These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31484992)

  • 1. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.
    Muhsen IN; Hashmi SK; Niederwieser D; Kroeger N; Agrawal S; Pasquini MC; Atsuta Y; Ballen KK; Seber A; Saber W; Kharfan-Dabaja MA; Rasheed W; Okamoto S; Khera N; Wood WA; Koh MBC; Greinix H; Kodera Y; Szer J; Horowitz MM; Weisdorf D; Aljurf M
    Bone Marrow Transplant; 2020 Apr; 55(4):698-707. PubMed ID: 31484992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.
    Muhsen IN; Hashmi SK; Niederwieser D; Kroeger N; Agrawal S; Pasquini MC; Atsuta Y; Ballen KK; Seber A; Saber W; Kharfan-Dabaja MA; Rasheed W; Okamoto S; Khera N; Wood WA; Koh MBC; Greinix H; Kodera Y; Szer J; Horowitz MM; Weisdorf D; Aljurf M
    Bone Marrow Transplant; 2020 Apr; 55(4):837. PubMed ID: 31616063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.
    Aljurf M; Weisdorf D; Hashmi SK; Nassar A; Gluckman E; Mohty M; Rizzo D; Pasquini M; Hamadani M; Saber W; Hari P; Kharfan-Dabaja M; Majhail N; Gerges U; Hamidieh AA; Hussain F; Elhaddad A; Mahmoud HK; Tbakhi A; Othman TB; Hamladji RM; Bekadja MA; Ahmed P; Bazarbachi A; Adil S; Alkindi S; Ladeb S; Dennison D; Patel M; Lu P; Quessar AE; Okamoto S; Atsuta Y; Alhejazi A; Ayas M; Ahmed SO; Novitzky N; Srivastava A; Seber A; Elsolh H; Ghavamzadeh A; Confer D; Kodera Y; Greinix H; Szer J; Horowitz M; Niederwieser D
    Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):7-16. PubMed ID: 31449781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and quality issues in establishing hematopoietic cell transplant program in developing countries.
    Hashmi SK; Srivastava A; Rasheed W; Adil S; Wu T; Jagasia M; Nassar A; Hwang WYK; Hamidieh AA; Greinix HT; Pasquini MC; Apperley JF; Aljurf M
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):167-172. PubMed ID: 28732192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
    Godman B; Haque M; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Allocati E; Bakar MA; Rahim SA; Sultana N; Deeba F; Halim Khan MA; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Acharya J; Sugahara T; Kwon HY; Bae S; Khuan KKP; Khan TA; Hussain S; Saleem Z; Pisana A; Wale J; Jakovljevic M
    Curr Med Res Opin; 2021 Sep; 37(9):1529-1545. PubMed ID: 34166174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations.
    Aljurf M; Weisdorf D; Hashmi S; Nassar A; Gluckman E; Mohty M; Rizzo D; Pasquini M; Hamadani M; Saber W; Hari P; Kharfan-Dabaja M; Majhail N; Gerges U; Hamidieh AA; Hussain F; Elhaddad A; Mahmoud HK; Tbakhi A; Othman TB; Hamladji RM; Bekadja MA; Ahmed P; Bazarbachi A; Adil S; Alkindi S; Ladeb S; Dennison D; Patel M; Lu P; Quessar AE; Okamoto S; Atsuta Y; Alhejazi A; Ayas MF; Ahmed SO; Novitzky N; Srivastava A; Seber A; Solh HE; Ghavamzadeh A; Confer D; Kodera Y; Hildegard G; Szer J; Horowitz MM; Niederwieser D
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2330-2337. PubMed ID: 31002990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars for breast cancer.
    Migliavacca Zucchetti B; Nicolò E; Curigliano G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.
    Cazap E; Jacobs I; McBride A; Popovian R; Sikora K
    Oncologist; 2018 Oct; 23(10):1188-1198. PubMed ID: 29769386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
    Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
    Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: Exploring the History, Science, and Progress.
    Tariman JD
    Clin J Oncol Nurs; 2018 Oct; 22(5):5-12. PubMed ID: 30239529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
    Bassi S; Stroppa EM; Moroni CF; Arbasi MC; Trabacchi E; Di Franco A; Lazzaro A; Bernuzzi P; Moretto M; Arcari A; Bosi C; Riva A; Cavanna L; Vallisa D
    Blood Transfus; 2015 Jul; 13(3):478-83. PubMed ID: 25761321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory considerations in biosimilars: Latin America region.
    Rathore AS; Bhargava A
    Prep Biochem Biotechnol; 2021; 51(2):201-206. PubMed ID: 33529091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory and clinical considerations for biosimilar oncology drugs.
    Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
    Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.
    Algwaiz G; Aljurf M; Koh M; Horowitz MM; Ljungman P; Weisdorf D; Saber W; Kodera Y; Szer J; Jawdat D; Wood WA; Brazauskas R; Lehmann L; Pasquini MC; Seber A; Lu PH; Atsuta Y; Riches M; Perales MA; Worel N; Okamoto S; Srivastava A; Chemaly RF; Cordonnier C; Dandoy CE; Wingard JR; Kharfan-Dabaja MA; Hamadani M; Majhail NS; Waghmare AA; Chao N; Kröger N; Shaw B; Mohty M; Niederwieser D; Greinix H; Hashmi SK;
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2181-2189. PubMed ID: 32717432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities.
    Morin S; Segafredo G; Piccolis M; Das A; Das M; Loffredi N; Larbi A; Mwamelo K; Villanueva E; Nobre S; Burrone E
    Lancet Glob Health; 2023 Jan; 11(1):e145-e154. PubMed ID: 36455593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.